|Bid||0.00 x 2900|
|Ask||0.00 x 900|
|Day's Range||8.15 - 8.63|
|52 Week Range||2.30 - 24.57|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Apr 28, 2014|
|1y Target Est||N/A|
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent, in heavily pre-treated breast cancer patients. Data will be presented at the American Society of Clinical Oncology 2021 Annual Meeting. In the overall Phase 2 study, the presence and the amount of AR receptor expression in breast cancer tissue correlated with a beneficial antitumor response. The best overall target lesion reduction of
Veru Inc (NASDAQ: VERU) has enrolled the first patient in its Phase 3 clinical trial evaluating sabizabulin (VERU-111) in high-risk hospitalized COVID-19 patients. Sabizabulin an oral cytoskeleton disruptor with anti-inflammatory and anti-viral properties. The 300-subject trial is evaluating daily oral doses of 9mg sabizabulin for up to 21 days versus placebo. Subjects in the sabizabulin and placebo arms will also be allowed to receive standard of care. The primary efficacy endpoint will be the proportion of patients that die on study up to Day 60. Secondary endpoints will include the proportion of patients without respiratory failure, days in ICU, Clinical Improvement, days on mechanical ventilation, days in the hospital, and viral load. Enrollment is targeted to be completed by year-end. Price Action: VERU shares are down 1.50% at $7.90 on the last check Wednesday. Related content: Benzinga's Full FDA Calendar See more from BenzingaClick here for options trades from BenzingaVeru's FC2 Prescription Sales Boost Q2 Revenues© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.